More Company News

Arecor Therapeutics

First patient dosed in Cohort 2 of the ModiFY Phase I clinical trial
16 Aug 2022Read More

Arecor Therapeutics

Q222 results
10 Aug 2022Read More

Arecor Therapeutics

First participant in IMG-004 Phase I trial
09 Aug 2022Read More

Arecor Therapeutics

EU patents for biosimilar Humira formulations
09 Aug 2022Read More

Arecor Therapeutics

SAVANNAH shows 49% ORR in high MET lung cancer
08 Aug 2022Read More

Arecor Therapeutics

FRESCO-2 meets primary endpoint in mCRC
08 Aug 2022Read More

Arecor Therapeutics

H122 interim results & business update
01 Aug 2022Read More

Arecor Therapeutics

Tazemetostat China bridging study in r/r FL starts
01 Aug 2022Read More

Arecor Therapeutics

Result of placing
01 Aug 2022Read More

Arecor Therapeutics

Proposed acquisition of Tetris Pharma Ltd
01 Aug 2022Read More

1 2 3 4 … 66
Return to Arecor Therapeutics
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).